Kleder (Lenalidomide)

Lenalidomide binds to cereblon, a component of the CRL4‑E3 ubiquitin ligase, leading to degradation of transcription factors Ikaros and Aiolos. This modulates immune responses, inhibits new blood‑vessel formation, and disrupts cytokine signaling, collectively producing anti‑tumor activity.

The specific dose of Kleder is determined by the prescribing clinician based on the patient’s diagnosis, disease stage, renal function, and other individual factors. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Lenalidomide is classified as pregnancy category X because it can cause severe fetal harm. It is contraindicated in pregnancy, and women of child‑bearing potential must use effective contraception. Breastfeeding is not recommended while taking lenalidomide.

To order Kleder, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Kleder (lenalidomide) belongs to the immunomodulatory drug class, offering a distinct mechanism from proteasome inhibitors or monoclonal antibodies. It is often used in combination regimens and provides oral administration, which can be advantageous over injectable alternatives for certain patient populations.

Kleder should be stored below 25 °C in its original packaging, protected from moisture and direct sunlight. Keep the product in a dry place and avoid exposing it to excessive heat or humidity to maintain its stability.

Kleder is taken orally, usually as a tablet swallowed with water. The exact timing (e.g., with or without food) and frequency are set by the prescriber, and patients should adhere to the prescribed schedule for optimal efficacy.

The most serious risks include venous thromboembolism, severe neutropenia or thrombocytopenia that can lead to infections or bleeding, and embryo‑fetal toxicity. Patients should be monitored regularly for blood‑cell counts and signs of clotting, and pregnancy must be avoided.

Kleder should not be used by pregnant women, individuals with known hypersensitivity to lenalidomide, or patients with uncontrolled infections. Caution is also advised for those with severe renal impairment or a history of thrombotic events.